{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:35:58Z","timestamp":1792290958613,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009278"],"award-info":[{"award-number":["APP2009278"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vaccine.2025.127868","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:27:44Z","timestamp":1762550864000},"page":"127868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies"],"prefix":"10.1016","volume":"68","author":[{"given":"Alessandra","family":"Bicego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Newall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2025.127868_bb0005","doi-asserted-by":"crossref","first-page":"444","DOI":"10.5694\/mja2.50173","article-title":"Assessing the burden of respiratory syncytial virus disease in Australia","volume":"210","author":"Moore","year":"2019","journal-title":"Med J Aust"},{"issue":"10340","key":"10.1016\/j.vaccine.2025.127868_bb0010","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127868_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2079322","article-title":"RSV disease in infants and young children: can we see a brighter future?","volume":"18","author":"Baraldi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127868_bb0020","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127868_bb0025","series-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","first-page":"1948","article-title":"Respiratory Syncytial Virus (RSV).","author":"Walsh","year":"2015"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127868_bb0030","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1542\/peds.2008-3074","article-title":"Relative impact of influenza and respiratory syncytial virus in young children","volume":"124","author":"Bourgeois","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127868_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1473-3099(23)00630-8","article-title":"Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis","volume":"24","author":"Cong","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127868_bb0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12889-017-4177-z","article-title":"Estimates of hospitalization attributable to influenza and RSV in the US during 1997\u20132009, by age and risk status","volume":"17","author":"Matias","year":"2017","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2025.127868_bb0045","article-title":"FDA approves first vaccine for pregnant individuals to prevent RSV in infants [internet]","author":"US Food and Drug Administration","year":"2024","journal-title":"FDA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127868_bb0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (maternal immunization study for safety and efficacy) maternal Respiratory Syncytial Virus Prefusion F protein vaccine trial","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2025.127868_bb0055","article-title":"FDA approves new drug to prevent RSV in babies and toddlers [internet]","author":"US Food and Drug Administration","year":"2024","journal-title":"FDA"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127868_bb0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health."},{"issue":"6","key":"10.1016\/j.vaccine.2025.127868_bb0065","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","article-title":"180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2025.127868_bb0070","author":"Centres for Disease Control. Respiratory Syncytial Virus Infection (RSV)"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127868_bb0075","article-title":"The recent landscape of RSV vaccine research","volume":"10","author":"Kelleher","year":"2025","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127868_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11539960-000000000-00000","article-title":"Modelling the epidemiology of infectious diseases for decision analysis","volume":"29","author":"Jit","year":"2011","journal-title":"PharmacoEconomics"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127868_bb0085","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S1473-3099(17)30232-3","article-title":"Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis","volume":"17","author":"Heath","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127868_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127868_bb0095","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.vaccine.2025.127868_bb0100","author":"Ankit Rohatgi. WebPlotDigitizer [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127868_bb0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","article-title":"Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis","volume":"18","author":"Hodgson","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2025.127868_bb0110","article-title":"Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination","volume":"38","author":"Hodgson","year":"2024","journal-title":"Lancet Reg Health \u2013 Eur"},{"issue":"49","key":"10.1016\/j.vaccine.2025.127868_bb0115","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1016\/j.vaccine.2022.10.041","article-title":"Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales","volume":"40","author":"Hodgson","year":"2022","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2025.127868_bb0120","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1016\/j.vaccine.2017.09.043","article-title":"Potential impact of a maternal vaccine for RSV: a mathematical modelling study","volume":"35","author":"Hogan","year":"2017","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2025.127868_bb0125","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.vaccine.2021.05.100","article-title":"Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand","volume":"39","author":"Prasad","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127868_bb0230","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127868_bb0145","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127868_bb0140","author":"World Health Organization"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127868_bb0155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory Syncytial Virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl. 7","key":"10.1016\/j.vaccine.2025.127868_bb0135","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1093\/infdis\/jiaa424","article-title":"Estimating transmission parameters for Respiratory Syncytial Virus and predicting the impact of maternal and pediatric vaccination","volume":"222","author":"van Boven","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127868_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-022-00550-5","article-title":"Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children","volume":"7","author":"Zheng","year":"2022","journal-title":"Npj Vaccines"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127868_bb0150","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F protein-based Respiratory Syncytial Virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127868_bb0235","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/S0264-410X(03)00352-9","article-title":"Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women","volume":"21","author":"Munoz","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127868_bb0240","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose Respiratory Syncytial Virus Prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127868_bb0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose Nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127868_bb0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-021-00566-9","article-title":"Potential impact of Nirsevimab on RSV transmission and medically attended lower Respiratory tract illness caused by RSV: a disease transmission model","volume":"11","author":"Voirin","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"388","key":"10.1016\/j.vaccine.2025.127868_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127868_bb0170","series-title":"Clinical guidance for RSV immunizations and vaccines","author":"Centres for Disease Control. Respiratory Syncytial Virus Infection (RSV)","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127868_bb0175","author":"UK National Health Service. nhs.uk"},{"key":"10.1016\/j.vaccine.2025.127868_bb0180","author":"Government of Canada."},{"key":"10.1016\/j.vaccine.2025.127868_bb0185","unstructured":"Australian Government Department of Health, Disability and Ageing. The Australian Immunisation Handbook, Respiratory syncytial virus (RSV) [Internet] [cited 2025 Mar 21]. Available from:. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccine-preventable-diseases\/respiratory-syncytial-virus-rsv; 2025."},{"issue":"6","key":"10.1016\/j.vaccine.2025.127868_bb0190","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","author":"L\u00f3pez-Lacort","year":"2024","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2025.127868_bb0195","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus\u2013associated hospitalization among infants entering their first respiratory syncytial virus season \u2014 new vaccine surveillance network, October 2023\u2013February 2024","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep [Internet]"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127868_bb0200","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2352-4642(24)00171-8","article-title":"Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case\u2013control study in Paris, France","volume":"8","author":"Carbajal","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127868_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106466","article-title":"Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024","volume":"90","author":"Wadia","year":"2025","journal-title":"J Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127868_bb0210","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127868_bb0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00285-021-01706-y","article-title":"Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review","volume":"84","author":"Lang","year":"2022","journal-title":"J Math Biol"},{"issue":"35","key":"10.1016\/j.vaccine.2025.127868_bb0220","article-title":"Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: a systematic review","volume":"1","author":"Mezei","year":"2021","journal-title":"Epidemics"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127868_bb0225","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40273-020-00991-7","article-title":"Assessment of the effects of active immunisation against Respiratory Syncytial Virus (RSV) using decision-analytic models: a systematic review with a focus on vaccination strategies, modelling methods and input data","volume":"39","author":"Treskova","year":"2021","journal-title":"PharmacoEcon"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:30:07Z","timestamp":1781663407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2501165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S0264410X2501165X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127868","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127868"}}